Tardive Dyskinesia: all 59 studies

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• A Computer-Assisted Tool for Objective Assessment of Extrapyramidal SymptomsNot yet recruitingNCT07715994
• Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive DyskinesiaRecruitingNCT07365462Phase 2
• Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TDRecruitingNCT07173920Not applicable
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingNCT07105111Phase 4
• Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental DisabilitiesRecruitingNCT06997198Phase 4
• Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive DyskinesiaRecruitingNCT06731868Phase 1/2
• Studying Patterns in Patient Engagement Among Tardive Dyskinesia PatientsNot yet recruitingNCT06218719
• Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient OutcomesRecruitingNCT06011408Not applicable
• Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as CorrelatesRecruitingNCT03495024Phase 4
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedNCT05859698Phase 4Results posted
• Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive DyskinesiaCompletedNCT03891862Phase 4Results posted
• The Potential for Clinical Dependence and Withdrawal Symptoms Associated With ValbenazineCompletedNCT03698331Phase 4Results posted
• Efficacy and Safety of MT-5199 in Subjects With Tardive DyskinesiaCompletedNCT03176771Phase 2/3Results posted
• Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive DyskinesiaCompletedNCT02736955Phase 3Results posted
• Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02405091Phase 3Results posted
• Addressing Involuntary Movements in Tardive DyskinesiaCompletedNCT02291861Phase 3Results posted
• A Phase 3 Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02274558Phase 3Results posted
• Reducing Involuntary Movements in Participants With Tardive DyskinesiaCompletedNCT02198794Phase 3Results posted
• Aim to Reduce Movements in Tardive DyskinesiaCompletedNCT02195700Phase 2/3Results posted
• Dysport for the Treatment of OMDCompletedNCT01921270Phase 1/2Results posted
• NBI-98854 Dose Titration Study for the Treatment of Tardive DyskinesiaCompletedNCT01733121Phase 2Results posted
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)CompletedNCT01688037Phase 2Results posted
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT01393600Phase 2Results posted
• Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release TabletsCompletedNCT06474650Phase 1
• Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy SubjectsCompletedNCT06216054Phase 1
• Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental DisabilitiesWithdrawnNCT06107829Phase 4
• A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy SubjectsCompletedNCT05238701Phase 1
• Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With ValbenazineWithdrawnNCT05053321Phase 1
• Pimavanserin Treatment in TSCompletedNCT04794413Early Phase 1
• Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive DyskinesiaCompletedNCT03497013Not applicable
• Randomized Controlled Trial of Pyridoxine for Tardive DyskinesiaCompletedNCT03287778Not applicable
• Safety and Efficacy of Propranolol in the Treatment of Tardive DyskinesiaWithdrawnNCT03254186Phase 2/3
• Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic AgentsStatus unknownNCT03062033
• Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.Status unknownNCT02840760Not applicable
• Deep Brain Stimulation for Patients With Tardive Dyskinesia and or DystoniaTerminatedNCT02524886Not applicable
• Validation of the Implantation of a New Electrode for the Treatment of DystoniaTerminatedNCT02509338Not applicable
• ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement DisordersActive, not recruitingNCT02252380Not applicable
• A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive DyskinesiaWithdrawnNCT02064010Phase 2
• Pyridoxal Kinase Activity in Tardive DyskinesiaWithdrawnNCT01908452Phase 3
• D-Serine Treatment For Tardive DyskinesiaStatus unknownNCT01804920Not applicable
• Xenazine in Late Dyskinetic Syndrome With NeurolepticsCompletedNCT01543321Phase 3
• The Assessment of Movement Disorders Utilizing Live Two-Way VideoCompletedNCT01467089
• Melatonin Treatment for Tardive Dyskinesia in SchizophreniaCompletedNCT01391390Not applicable
• Efficacy and Safety of NBI-98854 in Subjects With Tardive DyskinesiaCompletedNCT01267188Phase 2
• Tardive Dyskinesia and Cognitive FunctionCompletedNCT00926965Phase 4
• Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive DyskinesiaTerminatedNCT00917293Phase 2
• Aripiprazole for Neuroleptic-Induced Tardive DyskinesiaStatus unknownNCT00837707Phase 4
• Extract of Ginkgo Biloba and Tardive DyskinesiaCompletedNCT00672373Phase 3
• Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive DyskinesiaCompletedNCT00621998Phase 4
• Efficacy of Docosahexaenoic Acid on Tardive DyskinesiaWithdrawnNCT00621634Phase 2
• The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole TrialStatus unknownNCT00468533Phase 4
• Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in SchizophreniaCompletedNCT00401089Phase 1/2
• Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive DystoniaStatus unknownNCT00331669Phase 2
• Sarizotan in the Treatment of Neuroleptic-induced Tardive DyskinesiaTerminatedNCT00310661Not applicable
• Levetiracetam Treatment of Tardive DyskinesiaCompletedNCT00291213Phase 3
• Piracetam for Treatment Tardive DyskinesiaCompletedNCT00190008Phase 3
• Levetiracetam in the Treatment of Neuroleptic-induced Tardive DyskinesiaCompletedNCT00175955Phase 2
• Treatment of Tardive Dyskinesia With GalantamineCompletedNCT00164242Phase 4
• Ethyl-Eicosapentaenoic Acid and Tardive DyskinesiaCompletedNCT00114595Phase 4

← Tardive Dyskinesia overview